“Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2).”, Invest Ophthalmol Vis Sci, vol. 54, no. 7, pp. 4548-54, 2013.
, “Spectral-domain optical coherence tomography characteristics of intermediate age-related macular degeneration.”, Ophthalmology, vol. 120, no. 1, pp. 140-50, 2013.
, “Ten-year incidence rates of age-related cataract in the Age-Related Eye Disease Study (AREDS): AREDS report no. 33.”, Ophthalmic Epidemiol, vol. 20, no. 2, pp. 71-81, 2013.
, “Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial.”, Invest Ophthalmol Vis Sci, vol. 54, no. 4, pp. 2941-50, 2013.
, “The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1).”, Ophthalmology, vol. 119, no. 11, pp. 2282-9, 2012.
, “"En face" OCT imaging of the IS/OS junction line in type 2 idiopathic macular telangiectasia.”, Invest Ophthalmol Vis Sci, vol. 53, no. 10, pp. 6145-52, 2012.
, “The IS/OS junction layer in the natural history of type 2 idiopathic macular telangiectasia.”, Invest Ophthalmol Vis Sci, vol. 53, no. 12, pp. 7889-95, 2012.
, “Longitudinal analysis of retinal hemangioblastomatosis and visual function in ocular von Hippel-Lindau disease.”, Ophthalmology, vol. 119, no. 12, pp. 2622-30, 2012.
, “Spatial correlation between hyperpigmentary changes on color fundus photography and hyperreflective foci on SDOCT in intermediate AMD.”, Invest Ophthalmol Vis Sci, vol. 53, no. 8, pp. 4626-33, 2012.
, “Risk factors associated with incident cataracts and cataract surgery in the Age-related Eye Disease Study (AREDS): AREDS report number 32.”, Ophthalmology, vol. 118, no. 11, pp. 2113-9, 2011.
, “Baseline characteristics of participants in the natural history study of macular telangiectasia (MacTel) MacTel Project Report No. 2.”, Ophthalmic Epidemiol, vol. 17, no. 1, pp. 66-73, 2010.
, “Evaluation of the age-related eye disease study clinical lens grading system AREDS report No. 31.”, Ophthalmology, vol. 117, no. 11, pp. 2112-9.e3, 2010.
, “Natural history of drusenoid pigment epithelial detachment in age-related macular degeneration: Age-Related Eye Disease Study Report No. 28.”, Ophthalmology, vol. 117, no. 3, pp. 489-99, 2010.
, “Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema.”, Retina, vol. 30, no. 3, pp. 459-67, 2010.
, “Progression of geographic atrophy and genotype in age-related macular degeneration.”, Ophthalmology, vol. 117, no. 8, pp. 1554-9, 1559.e1, 2010.
, “Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial.”, Invest Ophthalmol Vis Sci, vol. 51, no. 12, pp. 6131-9, 2010.
, “Mitochondrial DNA variants of respiratory complex I that uniquely characterize haplogroup T2 are associated with increased risk of age-related macular degeneration.”, PLoS One, vol. 4, no. 5, p. e5508, 2009.
, “{omega}-3 Long-chain polyunsaturated fatty acid intake and 12-y incidence of neovascular age-related macular degeneration and central geographic atrophy: AREDS report 30, a prospective cohort study from the Age-Related Eye Disease Study.”, Am J Clin Nutr, vol. 90, no. 6, pp. 1601-7, 2009.
, “Omega-3 long-chain polyunsaturated fatty acid intake inversely associated with 12-year progression to advanced age-related macular degeneration.”, Arch Ophthalmol, vol. 127, no. 1, pp. 110-2, 2009.
, “Risk of advanced age-related macular degeneration after cataract surgery in the Age-Related Eye Disease Study: AREDS report 25.”, Ophthalmology, vol. 116, no. 2, pp. 297-303, 2009.
, “Summary results and recommendations from the age-related eye disease study.”, Arch Ophthalmol, vol. 127, no. 12, pp. 1678-9, 2009.
, “Visual acuity outcomes after cataract surgery in patients with age-related macular degeneration: age-related eye disease study report no. 27.”, Ophthalmology, vol. 116, no. 11, pp. 2093-100, 2009.
, “Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.”, Circulation, vol. 117, no. 16, pp. 2104-13, 2008.
, “Intravitreal ranibizumab therapy for retinal capillary hemangioblastoma related to von Hippel-Lindau disease.”, Ophthalmology, vol. 115, no. 11, pp. 1957-64, 2008.
, “The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project.”, Invest Ophthalmol Vis Sci, vol. 49, no. 10, pp. 4340-6, 2008.
,